文献速递糖尿病

使用KDIGO分类的1型糖尿病患者不良结局的负担与超额风险:一项全国队列研究

Burden and Excess Risk of Adverse Outcomes in Patients With Type 1 Diabetes Using KDIGO Classification: A National Cohort Study.
PubMed 文献 · Diabetes Care · 2025-01-01

基于瑞典国家糖尿病登记处40,199例1型糖尿病患者,平均随访9.1年,18.5%存在慢性肾脏病(eGFR<60 mL/min/1.73 m2和/或白蛋白尿)。随着KDIGO类别进展,所有研究结局的发生率和校正风险比逐步增加,包括传统上被视为非CKD的G2A1。

要点

  • 1型糖尿病中18.5%存在慢性肾脏病,KDIGO类别越高不良结局风险越高。
  • 即使eGFR保留且白蛋白尿正常(G2A1),所有结局风险仍超额。
  • eGFR≥105 mL/min/1.73 m2且无白蛋白尿未显示风险增加。

核心结论

  • 随着KDIGO类别进展,所有研究的不良结局负担逐步增加。
  • 即使eGFR保留且白蛋白尿正常(G2A1)的个体,传统上被视为非CKD,所有结局也存在超额风险。

研究设计与样本

  • 观察性队列研究,纳入瑞典国家糖尿病登记处40,199例1型糖尿病患者,最终分析39,067例,平均随访9.1年。

主要发现

  • 18.5%的患者存在慢性肾脏病,定义为eGFR<60 mL/min/1.73 m2和/或白蛋白尿。
  • 随着eGFR和白蛋白尿类别进展,所有研究结局的发生率和校正风险比逐步增加,包括G2A1(非CKD)。
  • eGFR≥105 mL/min/1.73 m2且无白蛋白尿与风险增加无关。

关键数值与推荐

  • 采用Cox回归分析,参考类别分别为:1)常规低风险「G1A1+G2A1」联合;2)单独「G1A1」以评估G2A1是否有超额风险;3)单独「G1bA1」以评估eGFR≥105 mL/min/1.73 m2是否有增加风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The widely adopted Kidney Disease: Improving Global Outcomes (KDIGO) classification system has been underused in assessing the burden and risk of adverse outcomes in type 1 diabetes. This observational study aimed to clarify how each KDIGO category correlates with adverse outcomes in this patient group. RESEARCH DESIGN AND METHODS: In a cohort of 40,199 individuals with type 1 diabetes from the Swedish National Diabetes Register, we aimed to investigate the 1) prevalence of different KDIGO categories at baseline; 2) incidence of adverse kidney and cardiovascular (CV) outcomes, including mortality, within each category; and 3) association of baseline category with excess risk of five outcomes: a 40% decline in estimated glomerular filtration rate (eGFR), kidney failure, major adverse kidney/CV events, and all-cause mortality. Cox regression analyses were conducted using three different reference categories: 1) the conventional low-risk "combined G1A1 + G2A1"; 2) "G1A1" alone to assess whether G2A1 had excess risk; and 3) "G1bA1" alone to evaluate whether eGFR ≥105 mL/min/1.73 m2 had increased risk. RESULTS: Among 39,067 included patients, with a mean follow-up of 9.1 years, 18.5% presented with chronic kidney disease (CKD), defined as eGFR <60 mL/min/1.73 m2 and/or albuminuria. A progressive increase in the incidence and adjusted hazard ratio for all studied outcomes was found with advancing eGFR and albuminuria categories, including in G2A1 (non-CKD). An eGFR ≥105 mL/min/1.73 m2 without albuminuria was not associated with increased risk. CONCLUSIONS: A progressively increasing burden of all studied adverse outcomes was observed with advancing KDIGO categories. Even individuals with preserved eGFR and normoalbuminuria (G2A1), conventionally perceived as non-CKD, had an excess risk for all outcomes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Makvandi K, Eliasson B, Carlsen HK, et al. Burden and Excess Risk of Adverse Outcomes in Patients With Type 1 Diabetes Using KDIGO Classification: A National Cohort Study. Diabetes Care. 2025. PMID: 39565836. doi:10.2337/dc24-0908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。